Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | RARA | P10276 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | RARG | P13631 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | NR1H2 | P55055 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gliquidone SCHEMBL37769 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| Gliquidone SCHEMBL15669239 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| Gliquidone SCHEMBL676846 | 0.99 | LMNA (0.98) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| SCHEMBL8216020 | 0.93 | LMNA (0.87) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| Gliquidone SCHEMBL28086518 | 0.91 | LMNA (0.82) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| Gliquidone SCHEMBL21824303 | 0.89 | CYP2C9 (0.79) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| Gliquidone SCHEMBL27714721 | 0.88 | CYP2C9 (0.78) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| SCHEMBL10281162 | 0.86 | CYP3A4 (0.76) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| SCHEMBL11929012 | 0.86 | CYP3A4 (0.76) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| SCHEMBL25866045 | 0.86 | CYP3A4 (0.75) | LMNACYP3A4CYP2C9ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376498-A1 | FUSION PROTEINS COMPRISING AN IMPROVED GLP-1 RECEPTOR AGONIST AND USES THEREOF | GUANGZHOU INNOGEN PHARMACEUTICAL GROUP CO LTD (CN) | 2025-12-11 | — | — | US | claimed |
| EP-3758692-B1 | COMPOSITIONS AND METHODS FOR TREATING PAIN | UNIV MARYLAND (US) | 2024-08-21 | — | — | EP | claimed |
| EP-4014999-B1 | COMBINATION PRODUCT CONTAINING LIMONIN COMPOUND AND SULFONYLUREA DRUG | ZHEJIANG YANGSHENGTANG INST OF NATURAL MEDICATION CO LTD (CN) | 2023-11-29 | — | — | EP | claimed |
| EP-3359162-B1 | METHODS OF TREATING INJURIES OR CONDITIONS RELATED TO CNS EDEMA | BIOGEN CHESAPEAKE LLC (US) | 2022-12-21 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3411026-B1 | USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS INC (US) | 2022-03-09 | — | — | EP | claimed |
| US-20260076972-A1 | ANTIDIABETIC MEDICATIONS | BOEHRINGER INGELHEIM INT (DE) | 2026-03-19 | — | — | US | disclosed |
| EP-4648849-A1 | NMU RECEPTOR 2 AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2025-11-19 | — | — | EP | disclosed |
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2025-10-09 | — | — | US | disclosed |
| US-12364700-B2 | Medical use of pharmaceutical combination or composition | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-07-22 | — | — | US | disclosed |
| US-12312352-B2 | Use of a DPP-4 inhibitor in SIRS and/or sepsis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-05-27 | — | — | US | disclosed |
| EP-4031108-B1 | EXTRUDED DEPOT FORM FOR CONTROLLED ACTIVE SUBSTANCE RELEASE | AMW GMBH (DE) | 2025-04-02 | — | — | EP | disclosed |
| US-20250082642-A1 | TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG | BOEHRINGER INGELHEIM INT (DE) | 2025-03-13 | — | — | US | disclosed |
| EP-2849754-B1 | LINAGLIPTIN, A XANTHINE DERIVATIVE AS DPP-4 INHIBITOR, FOR USE IN THE TREATMENT OF SIRS AND/OR SEPSIS | BOEHRINGER INGELHEIM INT (DE) | 2022-09-14 | — | — | EP | disclosed |
| EP-2397142-B1 | Use of DPP IV inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2022-07-27 | — | — | EP | disclosed |
| US-11369645-B2 | Hafnia alvei impact on regulation of appetite and metabolic syndrome aspects | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2022-06-28 | — | — | US | disclosed |
| US-20220184088-A1 | USES OF DPP IV INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-06-16 | — | — | US | disclosed |
| US-20220160717-A1 | Cardio- and Renosafe Antidiabetic Therapy | BOEHRINGER INGELHEIM INT (DE) | 2022-05-26 | — | — | US | disclosed |
| US-11291668-B2 | Uses of DPP IV inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-05 | — | — | US | disclosed |
| US-20220088023-A1 | ANTIDIABETIC MEDICATIONS | BOEHRINGER INGELHEIM INT (DE) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376498-A1 | FUSION PROTEINS COMPRISING AN IMPROVED GLP-1 RECEPTOR AGONIST AND USES THEREOF | GLP1R, GIPR, GCGR | LMNA 4415/4885CYP3A4 4606/4885CYP2C9 4524/4885 |
| US-20220184088-A1 | USES OF DPP IV INHIBITORS | DPP4, DPP3, DPP7 | LMNA 3770/4885CYP3A4 175/4885CYP2C9 627/4885 |
| US-20250082642-A1 | TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG | DPP4, DPP3, DPP7 | LMNA 4808/4885CYP3A4 129/4885CYP2C9 825/4885 |
| US-20220088023-A1 | ANTIDIABETIC MEDICATIONS | SLC5A1, SLC5A2, DPP4 | LMNA 3799/4885CYP3A4 599/4885CYP2C9 1458/4885 |
| US-11291668-B2 | Uses of DPP IV inhibitors | DPP4, DPP3, DPP7 | LMNA 3770/4885CYP3A4 175/4885CYP2C9 627/4885 |
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | LMNA 4606/4885CYP3A4 78/4885CYP2C9 376/4885 |
| US-12312352-B2 | Use of a DPP-4 inhibitor in SIRS and/or sepsis | DPP4, DPP3, DPP7 | LMNA 4617/4885CYP3A4 147/4885CYP2C9 1106/4885 |
| US-20260076972-A1 | ANTIDIABETIC MEDICATIONS | IAPP, DPP4, PYGL | LMNA 1252/4885CYP3A4 1702/4885CYP2C9 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.